Biomea Fusion Inc.
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
This study is a 52-week, phase 2 trial designed to examine whether treatment with icovamenib in participants with T2D who are currently on a GLP-1-based therapy will result in a greater reduction in HbA1c than GLP-1 based therapy alone. The current trial investigates participants who have used GLP-1 for at least 3 months prior to screening whose HbA1c remains above the target established by the ADA.
Key Inclusion Criteria: 1. Males or females, age ≥18 years and ≤75 years 2. Have been diagnosed with T2D 3. Taking FDA-approved GLP-1 based therapy (administered as subcutaneous injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening 4. Have HbA1c ≥7.0 and ≤10.5% 5. Have a BMI 25 to 45 kg/m2 6. Female participants of childbearing potential must have a negative pregnancy test, must be non-lactating, must be willing to have addi…
icovamenib 100 mg
Matching placebo